Robot-Assisted Radical Prostatectomy in High-Risk Prostate Cancer

Background. Prostate cancer (PC) is subdivided into risk categories according to patient prognosis. High-risk disease was previously typified by a higher risk of metastasis and mortality, which implied comprehensive treatment. Manifold studies have concluded that surgery is a key measure in such cases, even as monotherapy. Open radical prostatectomy (RP) was routinely performed in most high-risk PC patients until robot-assisted radical prostatectomy (RARP) had become a reasonable choice as improving outcomes in low- and intermediate-risk PC patients. Reliable RARP assessments in high-risk PC are still lacking. Th e review summarises published data on functional and oncological RARP outcomes in high-risk PC patients and analyses surgical inpatient cases at the BSMU Clinic for 2018—2021.

Materials and methods. The surgical outcomes in high-risk PC inpatients were analysed retrospectively at the BSMU Clinic for 2018—June 2021. Among 540 RARPs performed, 199 PC patients were identified as high-risk in the D’Amico criteria.

Results and discussion. Mean operation time was 100 min, blood transfusion rate — 3.5 %. Bladder catheterisation time was 5 days, average hospital stay — 7.1 days.

Conclusion. RARP may facilitate optimal therapeutic efficacy and favour postoperative recovery as monotherapy or the first step in a multimodal treatment of high-risk PC patients.

1. Yoo S., Lim B., Choi S.Y., You D., Kim C.S. Width of spared neurovascular bundle aft er robot-assisted laparoscopic prostatectomy in patients with prostate cancer: is it a reliable factor for predicting postoperative sexual outcome? Prostate Int. 2021;9(3):119–24. DOI: 10.1016/j. prnil.2020.07.005

2. Clinckaert A., Devos G., Roussel E., Joniau S. Risk stratifi cation tools in prostate cancer, where do we stand? Transl Androl Urol. 2021;10(1):12– 8. DOI: 10.21037/tau-20-1211

3. Fahmy O., Khairul-Asri M.G., Hadi S.H.S.M., Gakis G., Stenzl A. Th e role of radical prostatectomy and radiotherapy in treatment of locally advanced prostate cancer: a systematic review and meta-analysis. Urol Int. 2017;99(3):249–56. DOI: 10.1159/000478789

4. Yaxley J.W., Coughlin G.D., Chambers S.K., Occhipinti S., Samaratunga H., Zajdlewicz L., et al. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: Early outcomes from a randomised controlled phase 3 study. Lancet. 2016;388(10049):1057– 66. DOI: 10.1016/S0140-6736(16)30592-X

5. Urkmez A., Ranasinghe W., Davis J.W. Surgical techniques to improve continence recovery aft er robot-assisted radical prostatectomy. Transl Androl Urol. 2020;9(6):3036–48. DOI: 10.21037/tau.2020.03.36

6. Aas K., Berge V., Myklebust T.A., Fossa S.D. Comparative survival outcomes of high-risk prostate cancer treated with radical prostatectomy or defi nitive radiotherapy regimens. Eur Urol Open Sci. 2021;26:55–63. DOI: 10.1016/j.euros.2021.01.011

7. Matsuda Y., Narita S., Okubo T., Mitsuzuka K., Hatakeyama S., Koizumi A., et al. Impact of nerve-sparing status on positive surgical margin location and biochemical recurrence in patients with prostate cancer post radical prostatectomy. Ann Surg Oncol. 2021;28(9):5341–8. DOI: 10.1245/s10434-021-10281-x

8. Cooperberg M.R., Vickers A.J., Broering J.M., Carroll P.R. Comparative risk-adjusted mortality outcomes aft er primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer. 2010;116(22):5226–34. DOI: 10.1002/cncr.25456

9. Chun S.J., Kim J.H., Ku J.H., Kwak C., Lee E.S., Kim S. Comparison of radical prostatectomy and external beam radiotherapy in high-risk prostate cancer. Radiat Oncol J. 2021;39(3):231–8. DOI: 10.3857/ roj.2021.00486

10. Calleris G., Marra G., Dalmasso E., Falcone M., Karnes R.J., Morlacco A., et al. Is it worth to perform salvage radical prostatectomy for radio-recurrent prostate cancer? A literature review. World J Urol. 2019;37(8):1469–83. DOI: 10.1007/s00345-019-02749-z

11. Gandaglia G., De Lorenzis E., Novara G., Fossati N., De Groote R., Dovey Z., et al. Robot-assisted radical prostatectomy and extended pelvic lymph node dissection in patients with locally-advanced prostate cancer. Eur Urol. 2017;71(2):249–56. DOI: 10.1016/j. eururo.2016.05.008

12. McCormick B.Z., Chery L., Chapin B.F. Contemporary outcomes following robotic prostatectomy for locally advanced and metastatic prostate cancer. Transl Androl Urol. 2021;10(5):2178–87. DOI: 10.21037/tau-20-1002

13. Axén E., Godtman R.A., Bjartell A., Carlsson S., Haglind E., Hugosson J., et al. Degree of preservation of neurovascular bundles in radical prostatectomy and recurrence of prostate cancer. Eur Urol Open Sci. 2021;30:25–33. DOI: 10.1016/j.euros.2021.06.005

14. Yang C.W., Wang H.H., Hassouna M.F., Chand M., Huang W.J.S., Chung H.J. Prediction of a positive surgical margin and biochemical recurrence aft er robot-assisted radical prostatectomy. Sci Rep. 2021;11(1):14329. DOI: 10.1038/s41598-021-93860-y

15. Takahara K., Sumitomo M., Fukaya K., Jyoudai T., Nishino M., Hikichi M., et al. Clinical and oncological outcomes of robot-assisted radical prostatectomy with nerve sparing vs. non-nerve sparing for high-risk prostate cancer cases. Oncol Lett. 2019;18(4):3896–902. DOI: 10.3892/ol.2019.10692.

16. Walz J., Joniau S., Chun F.K., Isbarn H., Jeldres C., Yossepowitch O., et al. Pathological results and rates of treatment failure in highrisk prostate cancer patients aft er radical prostatectomy. BJU Int. 2011;107(5):765–70. DOI: 10.1111/j.1464-410X.2010.09594.x

17. Abdollah F., Sood A., Sammon J.D., Hsu L., Beyer B., Moschini M., et al. Long-term cancer control outcomes in patients with clinically highrisk prostate cancer treated with robot-assisted radical prostatectomy: Results from a multi-institutional study of 1100 patients. Eur Urol. 2015;68(3):497–505. DOI: 10.1016/j.eururo.2015.06.020

18. Blecher G., Almekaty K., Kalejaiye O., Minhas S. Does penile rehabilitation have a role in the treatment of erectile dysfunction following radical prostatectomy? F1000Res. 2017;6:1923. DOI: 10.12688/f1000research.12066.1

19. Kishore T.A., Kuriakose M.J., Raveendran V., Ramaprasad M.K. Th e impact of transition from conventional robot-assisted radical prostatectomy to retzius sparing robot-assisted radical prostatectomy: A retrospective multivariate analysis. Indian J Urol. 2021;37(2):140–6. DOI: 10.4103/iju.IJU_414_20

20. Jayram G., Decastro G.J., Large M.C., Razmaria A., Zagaja G.P., Shalhav A.L., et al. Robotic radical prostatectomy in patients with high-risk disease: A review of short-term outcomes from a High-Volume Center. J Endourol. 2011;25(3):455–7. DOI: 10.1089/end.2010.0349

21. Schifano N., Capogrosso P., Tutolo M., Dehò F., Montorsi F., Salonia A. How to prevent and manage post-prostatectomy incontinence: a review. World J Mens Health. 2021;39(4):581–97. DOI: 10.5534/wjmh.200114

22. Cordes L.M., Schmidt K.T., Peer C.J., Chau C.H., Redmond E., Francis D., et al. Study to compare capsule and liquid formulations of enzalutamide after single-dose administration under fasting conditions in prostate cancer. Oncologist. 2021;26(9):729-e1493. DOI: 10.1002/onco.13919

23. Nyarangi-Dix J.N., Tosev G., Damgov I., Reimold P., Aksoy C., Hatiboglu G., et al. Recovery of pad-free continence in elderly men does not diff er from younger men undergoing robot-assisted radical prostatectomy for aggressive prostate cancer. World J Urol. 2019;38(2):351–60. DOI: 10.1007/s00345-019-02797-5

24. Yossepowitch O., Eggener S.E., Serio A.M., Carver B.S., Bianco F.J. Jr, Scardino P.T., et al. Secondary therapy, metastatic progression, and cancer-specifi c mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol. 2008;53(5):950–9. DOI: 10.1016/j.eururo.2007.10.008

25. Nguyen C.T., Reuther A.M., Stephenson A.J., Klein E.A., Jones J.S. Th e specifi c defi nition of high risk prostate cancer has minimal impact on biochemical relapse-free survival. J Urol. 2009;181(1):75–80. DOI: 10.1016/j.juro.2008.09.027

26. Venclovas Z., Jievaltas M., Milonas D. Signifi cance of time until PSA recurrence aft er radical prostatectomy without neo- or adjuvant treatment to clinical progression and cancer-related death in high-risk prostate cancer patients. Front Oncol. 2019;9:1286. DOI: 10.3389/ fonc.2019.01286

27. Stroup S.P., Moreira D.M., Chen Z., Howard L., Berger J.H., Terris M.K., et al. Biopsy detected gleason pattern 5 is associated with recurrence, metastasis and mortality in a cohort of men with high risk prostate cancer. J Urol. 2017;198(6):1309–15. DOI: 10.1016/j. juro.2017.07.009

28. Vernooij R.W., Lancee M., Cleves A., Dahm P., Bangma C.H., Aben K.K. Radical prostatectomy versus deferred treatment for localised prostate cancer. Cochrane Database Syst Rev. 2020;6(6):CD006590. DOI: 10.1002/14651858.CD006590.pub3